Track the Kalaris Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €99.3m. The latest transaction was filed on 22 May 2026 (Acquisition). Among the most active insiders: AKKARAJU SRINIVAS. Every trade is accessible without an account.
12
Insider Decl.
n/a
Thresholds
€5m
2 ops.
Buy Volume
€18,657
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kalaris Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$18.71.
27Σ signal
Buys €5m€18,657 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Kalaris Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades graves. Cotiza en el NASDAQ bajo el ticker XNAS.